개미가 데이터를 나르는 중입니다…
6 stages · 20 listed names screened
Scored on valuation multiples, profitability and 52-week price position. Sorted by score. Data as of 2026-08-08.
| Company | Sector | Verdict | Score | P/E | P/B | ROE |
|---|---|---|---|---|---|---|
| 휴메딕스200670.KQ | Pharma & Bio | Undervalued | 75 | 5.8 | 1.00 | 17.1% |
| JW중외제약001060.KS | Pharma & Bio | Undervalued | 73 | 8.1 | 1.59 | 19.6% |
| 보령003850.KS | Pharma & Bio | Undervalued | 72 | 7.2 | 0.89 | 12.5% |
| 유나이티드제약 |
Company pages and the full analysis are in Korean. Korean version of this page → Compiled from public disclosures and market data for reference only. Not investment advice.
| Pharma & Bio |
| Undervalued |
| 70 |
| 7.3 |
| 0.64 |
| 8.7% |
| 대웅003090.KS | Pharma & Bio | Undervalued | 70 | 5.7 | 0.89 | 15.7% |
| 파미셀005690.KS | Pharma & Bio | Undervalued | 70 | 15.4 | 5.42 | 35.1% |
| 명인제약317450.KS | Pharma & Bio | Undervalued | 69 | 7.9 | 0.85 | 10.8% |
| 유한양행우000105.KS | Pharma & Bio | Undervalued | 69 | 0.4 | 0.03 | 9.2% |
| 종근당홀딩스001630.KS | Pharma & Bio | Undervalued | 69 | 4.2 | 0.31 | 7.4% |
| 동구바이오제약006620.KQ | Pharma & Bio | Undervalued | 68 | 2.2 | 0.73 | 33.2% |
| JW생명과학234080.KS | Pharma & Bio | Undervalued | 68 | 6.2 | 0.83 | 13.2% |
| 동아쏘시오홀딩스000640.KS | Pharma & Bio | Undervalued | 67 | 6.4 | 0.53 | 8.2% |
| JW홀딩스096760.KS | Pharma & Bio | Undervalued | 67 | 4.2 | 1.09 | 25.9% |
| 유바이오로직스206650.KQ | Pharma & Bio | Undervalued | 66 | 10.9 | 1.82 | 16.7% |
| 대웅제약069620.KS | Pharma & Bio | Undervalued | 66 | 7.5 | 1.49 | 19.9% |
| 중앙백신072020.KQ | Pharma & Bio | Undervalued | 66 | 11.7 | 0.82 | 7.0% |
| 옵투스제약131030.KQ | Pharma & Bio | Fair value | 65 | 8.1 | 0.62 | 7.7% |
| 대한뉴팜054670.KQ | Pharma & Bio | Fair value | 64 | 5.3 | 0.59 | 11.2% |
| SK바이오팜326030.KS | Pharma & Bio | Fair value | 64 | 19.2 | 8.23 | 42.9% |
| 위더스제약330350.KQ | Pharma & Bio | Fair value | 64 | 12.6 | 0.94 | 7.4% |